📊 MRNA Key Takeaways
Is Moderna, Inc. (MRNA) a Good Investment?
Moderna faces a fundamental deterioration in its business with 39.9% revenue decline and operating losses of $1.4B, driven by post-COVID vaccine demand normalization. While the balance sheet remains solid with $1.9B in cash and low debt, the company is burning $630M+ annually in operations, creating an unsustainable 3-year cash runway without major business repositioning.
Fundamentals show steep revenue contraction and heavy losses, with deeply negative operating and free cash flow margins. However, a strong balance sheet with ample liquidity and low leverage provides runway to execute and narrow losses. Await evidence of revenue stabilization and improved operating efficiency before a more constructive stance.
Why Buy Moderna, Inc. Stock? MRNA Key Strengths
- Strong balance sheet with low debt-to-equity ratio (0.08x) and minimal financial leverage
- Excellent liquidity position with 2.41x current ratio providing flexibility
- Net loss improving 20.8% year-over-year, indicating management actions are reducing losses
- Ample liquidity (3.29x current, $2.60B cash) supporting runway
- Low leverage (0.07x D/E) and modest long-term debt
- Large equity base ($8.65B) and YoY improvement in net loss
MRNA Stock Risks: Moderna, Inc. Investment Risks
- Catastrophic 39.9% YoY revenue decline with no evidence of stabilization or recovery
- Operating and free cash flow deeply negative (-$630M and -$692M respectively) indicating unsustainable burn rate
- Losses so severe that profitability timeline is uncertain, threatening enterprise viability if trends continue
- Revenue down 39.9% YoY, indicating weak demand momentum
- Sustained negative operating margin (-158%) and FCF margin (-106%)
- Ongoing cash burn with non-meaningful interest coverage raises financing/execution risk
Key Metrics to Watch
- Revenue stabilization and growth recovery - critical indicator of business viability
- Operating cash flow trend - must move toward positive territory within 18-24 months
- Cash runway depletion rate relative to cost restructuring success
- Revenue YoY growth
- Free cash flow
Moderna, Inc. (MRNA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.41x current ratio provides a solid financial cushion.
MRNA Profit Margin, ROE & Profitability Analysis
MRNA vs Healthcare Sector: How Moderna, Inc. Compares
How Moderna, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Moderna, Inc. Stock Overvalued? MRNA Valuation Analysis 2026
Based on fundamental analysis, Moderna, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Moderna, Inc. Balance Sheet: MRNA Debt, Cash & Liquidity
MRNA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Moderna, Inc.'s revenue has grown significantly by 11,274% over the 5-year period, indicating strong business expansion. The most recent EPS of $-12.33 indicates the company is currently unprofitable.
MRNA Revenue Growth, EPS Growth & YoY Performance
MRNA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $108.0M | -$971.0M | $-2.52 |
| Q3 2025 | $1.0B | $13.0M | $0.03 |
| Q2 2025 | $142.0M | -$825.0M | $-2.13 |
| Q1 2025 | $108.0M | -$971.0M | $-2.52 |
| Q3 2024 | $1.8B | $13.0M | $0.03 |
| Q2 2024 | $241.0M | -$1.3B | $-3.33 |
| Q1 2024 | $167.0M | $79.0M | $0.19 |
| Q3 2023 | $1.8B | $1.0B | $2.53 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Moderna, Inc. Dividends, Buybacks & Capital Allocation
MRNA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Moderna, Inc. (CIK: 0001682852)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MRNA
What is the AI rating for MRNA?
Moderna, Inc. (MRNA) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MRNA's key strengths?
Claude: Strong balance sheet with low debt-to-equity ratio (0.08x) and minimal financial leverage. Excellent liquidity position with 2.41x current ratio providing flexibility. ChatGPT: Ample liquidity (3.29x current, $2.60B cash) supporting runway. Low leverage (0.07x D/E) and modest long-term debt.
What are the risks of investing in MRNA?
Claude: Catastrophic 39.9% YoY revenue decline with no evidence of stabilization or recovery. Operating and free cash flow deeply negative (-$630M and -$692M respectively) indicating unsustainable burn rate. ChatGPT: Revenue down 39.9% YoY, indicating weak demand momentum. Sustained negative operating margin (-158%) and FCF margin (-106%).
What is MRNA's revenue and growth?
Moderna, Inc. reported revenue of $389.0M.
Does MRNA pay dividends?
Moderna, Inc. does not currently pay dividends.
Where can I find MRNA SEC filings?
Official SEC filings for Moderna, Inc. (CIK: 0001682852) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MRNA's EPS?
Moderna, Inc. has a diluted EPS of $-3.40.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MRNA a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Moderna, Inc. has a SELL rating with 76% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MRNA stock overvalued or undervalued?
Valuation metrics for MRNA: ROE of -18.1% (sector avg: 15%), net margin of -345.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MRNA stock in 2026?
Our dual AI analysis gives Moderna, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MRNA's free cash flow?
Moderna, Inc.'s operating cash flow is $-630.0M, with capital expenditures of $62.0M. FCF margin is -177.9%.
How does MRNA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -345.2% (avg: 12%), ROE -18.1% (avg: 15%), current ratio 2.41 (avg: 2).